News for Dermata Therapeutics, Inc. (DRMA)

Dermata Therapeutics (DRMA) has recently received an updated analyst action from Maxim Group. The firm has decided to maintain its "Buy" rating on the stock. Ho

An analysis from Maxim has resulted in a revised price target for Dermata Therapeutics (DRMA), reducing it to $3 from the previous target of $6, while maintaini

As of the end of the fiscal quarter on March 31, 2025, DRMA reported holding $9.7 million in cash and cash equivalents, a significant rise from $3.2 million at

Dermata Therapeutics (DRMA) has reported encouraging outcomes for its XYNGARI Phase 3 STAR-1 clinical trial, aiming to treat moderate-to-severe acne. The trial'

Phase 3 STAR-1 trial for XYNGARIâ„¢ achieved all primary endpoints with statistical significance. Demonstrated rapid efficacy with significant resul

Dermata Therapeutics, Inc. (DRMA) has finalized an agreement for the immediate exercise of existing warrants, enabling the purchase of 4,834,470 of their common

March 28, 2025 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com), a go-to platform for big investing ideas for stock traders, including bio...

Portage Biotech Inc (PRTG), a clinical stage immune-oncology company is up over 155 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.

Shares of Braze, Inc. BRZE rose sharply in today's pre-market trading after the company reported better-than-expected fourth-quarter financial results and issue...

U.S. stock futures fell on Friday after two consecutive days of decline on Wednesday and Thursday. Futures of benchmark indices were lower.

SAN DIEGO, CA / ACCESS Newswire / March 27, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnol

U.S. stocks traded lower midway through trading, with the Dow Jones index falling around 90 points on Thursday. The Dow traded down 0.23% to 42,358.68 while th...

U.S. stocks traded lower this morning, with the Nasdaq Composite falling more than 100 points on Thursday. Following the market opening Thursday, the Dow trade...

Dermata Therapeutics, Inc. (DRMA) Thursday reported positive topline results from the pivotal Phase 3 STAR-1 study of the company's lead product candidate Xyngari for the treatment of acne.

- Dermata expects to announce topline results from its XYNGARIâ„¢ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial by end of March 2025 -- T

Dermata Therapeutics (DRMA) reports FY GAAP EPS of -$8.03, outperforming estimates.

PR NewswireSAN DIEGO, March 4, 2025 - STAR-1 topline results expected by the end of March 2025 -- Over 30 million acne patients seek treatment in the U.S.

- This would be Dermata's second patent for DMT410, if issued, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis -- The Comp

On December 31, 2024, ARMISTICE CAPITAL, LLC (Trades, Portfolio) made a strategic move by acquiring 276,422 shares of Dermata Therapeutics Inc at a price of $1.